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reached the therapeutic target set by the K/DOQI Guidelines (P< 5.5 mg/dL). The 
economic evaluation was conducted according to the hospital perspective and were 
considered the only consumption associated with the purchase of the drugs admin-
istered. Results: The combination of LC plus standard therapy has produced a 
significant increase in the percentage of patients who achieved the target range as 
defined by the K/DOQI Guidelines (+85.16%). The reduction of 21.2 mg/dL (-32.7%) 
mean phosphorus in FP (4,55 mg/dL) than in the FR (6.77 mg/dL) was statistically 
significant (p < 0.001). The average expected cost/year for patients treated with LC 
plus standard therapy (€ 2,527.88) was higher of € 419.60 (+ 16.6%) compared to the 
standard therapy alone (€ 2,108.28). The analysis of cost-effectiveness showed an 
incremental cost per patient to therapeutic target of € 492.69 for LTS compared to 
TS (projected annual cost). ConClusions: The introduction of the LC in the treat-
ment of hemodialysis patients with uncontrolled hyperphosphatemia is very cost-
effective and has allowed a significant increase in the achievement of therapeutic 
targets with minimal increase in costs for the National Health System.
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes & Patient Preference 
Studies
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objeCtives: Nocturia is defined by the International Continence Society as the 
complaint of ‘waking to void 1 or more times a night followed by sleep’. The most 
common cause is nocturnal polyuria (NP - nocturnal urine overproduction). While 
recognised as bothersome, it is often under-recognised as a separate condition and 
thus treated by medications for overactive bladder (OAB) or benign prostate hyperpla-
sia (BPH), and not by an antidiuretic recommended for hormonal/renal dysfunctions, 
for example desmopressin. This analysis investigates the potential under-treatment 
of nocturia in a real world setting. Methods: Data were drawn from a 2013 cross-
sectional survey of physicians and consulting patients. Primary care physicians (264) 
and urology specialists (371) in France, Germany, Spain, UK and USA, actively manag-
ing urology patients, completed patient record forms prospectively for the next 14 
OAB/BPH/nocturia patients who consulted. Results: Physicians provided records 
on 8738 patients, of which 569 had a primary diagnosis of nocturia or NP. There was 
substantial variation in treatment: 46% received an OAB treatment, 16% a BPH treat-
ment, 7% other treatments, 21% no treatment, and 16% received desmopressin. There 
was considerable frequency in switching to second or third line treatments. After 
a mean of 16 months, 132 of the nocturia patients (23%) switched to a new treat-
ment. Among these, 19% switched again after 13 months. Nocturia patients receiving 
desmopressin at some point were more likely to be satisfied with, and continue their 
current treatment, compared to those on BPH or OAB medications. ConClusions: 
The real-world survey suggests nocturia treatment is far from optimal in view of the 
need to frequently switch treatment modalities offering distinctly differing pharma-
codynamic actions. Prescribing bladder or prostate medications for a renal condition, 
or withholding treatment, could potentially lead to considerable drug waste, extra 
physician visits, delay of most appropriate treatment and impaired quality of life.
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objeCtives: Nocturia (getting up at night to void) can have a negative impact on 
quality of life (QoL), but limited data are available to determine the size of this impact. 
This study aimed to derive utility data on the impact of nocturia on QoL from the 
randomised clinical trial CS29 (clinicaltrials.gov; NCT00477490) for desmopressin ver-
sus placebo. Methods: SF-12 data collected at three time-points in CS29 (n= 803, 
male= 434, female= 369) were mapped to utility values using the SF-6D. Multiple data 
points were available per patient; a mixed model, with patient as a random effect 
variable, was therefore fitted using the generalised additive mixed model procedure in 
R. Utilities were produced accounting for the difference in various potentially clinical 
significant factors: age, body mass index, gender, number of co-morbidities, number 
of voids (NOV) and time to first void (TTV, also called first uninterrupted sleep period - 
FUSP). Diagnostic plots were produced to test model fit (scatter, residual and Q-Q), and 
Spearman rank correlations were calculated for all pairwise comparisons to test for 
multicollinearity in the data. For calculation of predictive utilities, all variables were 
set to their median values. Results: All diagnostic plots showed a good model fit 
and no violation of model assumptions. Though multicollinearity was found between 
NOV (median= 3.33 voids) and TTV (median= 1.78h), both variables were kept in the 
model to determine their relative impact on QoL. Both NOV and TTV had a significant 
impact on utility, with up to 0.1 change in score. The utility was 0.75, 0.72 and 0.69 
for [0;2[, [2;4[ and [4;+∞[ voids per night, respectively. Age presented with the lowest 
utility score for patients aged 40-50. Male patients had a higher score than female 
patients. ConClusions: Nocturia severity has a significant impact on QoL. NOV and 
TTV can cause changes up to 0.1 in utility score.
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objeCtives: LUTS (lower urinary tract symptoms) are highly frequent and bother-
some to the patient. Nocturia, defined by the International Continence Society as 
4mg. The resulting incremental cost effectiveness ratio (ICER) was € 15,388/QALY 
gained. The probability of mirabegron 50 mg/day being cost-effective relative to 
tolterodine 4mg/day was 81.9% at a willingness to pay threshold of € 30,000/QALY. 
Incremental cost-effectiveness ratios of mirabegron 50mg/day versus solifenacin 
5 and 10 mg/day were € 2,536 and € 4,837 per QALY gained, respectively. The prob-
ability of cost effectiveness for mirabegron 50mg/day was 90.0% and 90.5% versus 
solifenacin 5 and 10 mg/day respectively. Mirabegron 50mg/day was the dominant 
treatment (more effective with lower costs) versus fesoterodine 4 and 8 mg/day with 
a probability of cost-effectiveness of 93.8% and 93.1%, respectively. ConClusions: 
Mirabegron 50 mg/day is a cost-effective treatment compared with antimuscarin-
icagents in OAB patients from a Spanish NHS perspective.
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bACkgRound: Immunosuppresive therapy after organ transplantation is financed 
from federal budget in Russia, but only when certain drugs are prescribed, i.e. 
mycophenolic acid, mycophenolate mofetil, cyclosporine, tacrolimus. Everolimus 
had demonstrated good efficacy and safety in renal transplantation patients but has 
not been included into federal drug provision program yet. objeCtives: to calculate 
cost difference between two approaches for immunosuppressive therapy after renal 
transplantation: everolimus plus reduced-exposure cyclosporine (Ev+Cyc_red) and 
mycophenolic acid plus standard-exposure cyclosporine (MA+Cyc_st) for Russian 
healthcare system. Methods: We calculated the two-year difference in costs that 
resulted from efficacy and safety differences of compared alternatives employing 
the probability model. Data on safety and efficacy of compared strategies were 
taken from D. Cibrik et al. randomized control trial (2013). Direct medical costs were 
calculated from the Russian healthcare system point of view. We also estimated 
the 5-year budget impact of everolimus inclusion into the drug provision program 
financed from federal budget. Results: Ev+Cyc_red leads to cost reduction by € 2.5 
thousands (17%) per patient in a two-year period when compared to MA+Cyc_st. The 
reduction mainly results from less costs for immunosuppressive drugs in Ev+Cyc_
red approach compared to MA+Cyc_st. Also costs for cytomegalovirus infection 
prevention and treatment are smaller in Ev+Cyc_red strategy. Everolimus inclu-
sion into federal drug provision program will lead to reduction in federal budget 
spending starting from the first year; the total five-year budget savings are € 4.3 
million. ConClusions: Ev+Cyc_red is a cost-saving option for immunosuppres-
sive therapy after renal transplantation in Russia when compared with MA+Cyc_st.
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objeCtives: Laparoscopic surgery is commonly used to remove the kidney 
from a donor in kidney transplant but was recently used for the first time in the 
UK to implant the kidney. The objective of this study was to analyse the cost-
effectiveness of using laparoscopic surgery compared to open surgery in kidney 
recipients. Methods: A decision tree model with a time-horizon of 10 days was 
constructed to capture short-term costs and benefits of patients undergoing kidney 
transplantation. The model was built from a third-party payer perspective in the UK. 
The costs for work-up, surgery, blood transfusion during surgery, equipment, hospi-
tal stay and post-operative complications were informed by National Health Service 
reference costs and published literature. The utilities for a patient during surgery 
(0.00), during recovery (0.48), with complications after surgery (0.40) and after being 
released from hospital (0.84) were derived from published literature. Results: The 
total costs for the laparoscopic surgery arm were lower than those for open sur-
gery arm (£25,891 versus £25,962) – although the laparoscopic procedure itself was 
more expensive, the costs were offset by savings from reduced blood loss and lower 
risk of complications. The total quality adjusted life years (QALYs) were higher for 
laparoscopic surgery (0.01718 versus 0.01369) because of the lower number of days 
needed for recovery. At a threshold of £20,000 per QALY, the probability that laparo-
scopic surgery is cost effective was 0.595. The key drivers of the model were lengths 
of hospital stay after open and laparoscopic surgery and duration of laparoscopic 
surgery. The incremental cost effectiveness ratio was dominant in the base case but 
could be as high as £78,468 if risk of complications after open surgery decreases from 
0.512 to 0.368. ConClusions: This study suggests that the laparoscopic surgery 
improves quality of life at a lower cost, but is subject to uncertainty.
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PhARmAcOEcONOmIc ANAlYSIS: ANAlYSIS Of cOSt-EffEctIvENESS Of 
lANthANUm-cARbONAtE (lc) IN UNcONtROllED hYPERPhOSPhAtEmIA IN 
DIAlYSIS
Giotta N, Marino AM
Cardinal Massaia Hospital, ASTI, Italy
objeCtives: The objective of this study is to evaluate the difference in terms of 
efficacy and costs of lanthanum carbonate plus standard therapy (LTS) compared 
to standard therapy alone (TS) in the treatment of hemodialysis patients with 
persistent hyperphosphatemia. Methods: We selected 14 consecutive patients 
(8 males and 7 females) on hemodialysis with more than four phosphorus values 
greater than 6 mg/dL in three months, got them recruited in therapy with lantha-
num carbonate. The data analysis has been done considering a phase retrospective 
(FR) of three months and a phase perspective (FP) of six months, analyzing for each 
subject consumption and the effectiveness of therapy before and after enrollment. 
The effectiveness of treatment, was evaluated as the percentage of patients who 
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Gerlichova K, Bielik J, Papsova D, Melus V
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objeCtives: The prevalence of urinary incontinence (UI) in women in Slovakia is 
about 240 000 cases and has an increasing trend. Only 5 % of them were diagnosed 
by visiting urology or gynecology outpatient department. The objective of this paper 
was to find out the level of QoL in women with UI in Slovakia. Methods: The 
primary method used for the analysis of QoL was the combined questionnaire 
consisting of 6 parts: A. Demography (9 items), B. Clinical part (B1- International 
Consultation on Incontinence (ICIQ-SF): 4 items, B2- characteristics of UI: 23 items), 
C. Quality of life with dominant numeric scale (13 items), D. Socio-economic part (9 
items), E. EQ-5D (5 items), F. Symptoms of disease (9 items). There were 112 patients 
in the examined group from the160 asked to fill the questionnaire. The average age 
was 61 years. Results: Present level of QoL was identified as 6,60 on the scale from 
1 to 10 (1- the worst,10 –the best), while in the time of the UI diagnosis it was 5,10. 
QoL was 8,10 in the time without UI and 9,40 in the total optimal state of health. 
Comparative to the QoL was examined the ability to work (AW), too. Present level 
of AW was identified as 6,50, while in the time of the BC diagnosis it was 5,50. AW 
was 8.20 in the time without UI and 9,40 in the total optimal state of health. The 
impact of treatment on QoL was 7,60 and the disease had impact 7,40 on family 
QoL. The average income was 465,04 € and the willingness to pay for 1 month of 
complete health was in average 391,06 € . ConClusions: The disease had a sig-
nificant impact on patients´s QoL. The treatment of UI had a significant impact on 
increasing QoL of patients.
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objeCtives: The purpose of the study is to investigate how the QOL of parents 
whose child had received pediatric kidney tranplantation(KT) would change by 
delivering questionnaires for four times a year. Methods: The QOL of thirty-one 
parents with a mean age of 38.5 yrs old (30 mothers, 1 father) whose child received 
KT at Toho Ohmori Hospital in Tokyo from May 2012 to March 2015 was measured 
using WHOQOL, GHQ, and VAS for four times; before, one month, three months, 
one year after KT. The mean age of receipient patients was 5.8 yrs old (18 boys, 13 
girls). Congenital anomalies of the kidney and urinary tract were most frequent 
primary diseases. Among them twenty-two children received dialysis before KT, 
and nine received preemtive KT. Results: Based on the results of WHOQOL, the 
QOL of parents dropped with a statistical difference one month after KT, compared 
with before KT (p= 0.042), but rose at three months (p= 0.0073), and maintained 
until one year. The QOL of parents with child with frequent infections was statisti-
cally lower than those without any infectionat three months after KT (p= 0.448) 
and one year after KT (P= 0.0406). The QOL scores of nineteen donor parents had a 
statistically higher QOL before KT, but reversed at one month after KT particurally 
in physical domain of WHOQOL, but became higher again at three month after 
KT, compared with the rest of parents. ConClusions: The QOL of the parents 
would change in the process recovery of child, and with infection or other medi-
cal problems occurred, QOL reflected it, but three months after KT, QOL rose as 
high as before KT.
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objeCtives: Nocturia is defined by the International Continence Society as 
the need to void one or more times during the night, with each of the voids 
preceded and followed by sleep. The chronic sleep disturbance and sleep depri-
vation suffered by nocturia patients impacts their entire health-related quality 
of life, compromising both mental and physical well-being. This review aims 
to better characterise the societal burden of nocturia by comparing published 
data from nocturia patients with those of 12 other common chronic conditions, 
specifically focussing on the impact on work productivity and activity impair-
ment, as measured by the WPAI (Work Productivity and Activity Impairment) 
instrument. Methods: Systematic searches of Medline and the WPAI database 
returned 241 publications, after removal of duplicates, 178 publications were 
screened, and 79 evaluable studies were identified for inclusion in the review. 
Most exclusions were due to duplicate publication of the same study or insuf-
ficient WPAI data presented. Data extraction recorded study and summary-level 
patient characteristics and all reported WPAI data on overall work productiv-
ity impairment and overall activity impairment. Results: The number of 
evaluable studies, the number of different disease-specific subgroups with 
WPAI data and the range of overall work productivity impairment reported, 
respectively, were as follows: nocturia (3, 10, 14-39%); overactive bladder (6, 6, 
11-41%); irritable bowel syndrome/ constipation (11, 13, 25-40%); GERD (13, 15, 
13-33%); asthma/ allergies (11, 15, 6-40%); COPD (7, 9, 21-42%); sleep problems (2, 
3, 12-37%); arthritis (12, 16, 21-69%); pain (8, 9, 29-52%); depression (4, 5, 15-43%); 
and gout (2, 2, 20-37%). ConClusions: The overall work productivity impair-
ment of nocturia is substantial and found to be similar to several other more 
frequently researched common chronic diseases. Greater awareness of the bur-
den of nocturia, a highly bothersome and prevalent condition, will help policy-
makers and healthcare decision-makers to provide appropriate management of 
nocturia.
‘waking to void 1 or more times a night followed by sleep’, is reported as being the 
most bothersome of these symptoms. The most frequent cause of nocturia is noctur-
nal polyuria (NP, overproduction of urine during the night defined as ≥ 33% of total 
urine volume). While there are well-known negative effects of nocturia on Health-
related Quality of Life, there is limited information on the relationship between NP 
disease severity, as defined by the number of nightly voids, and utility. Methods: 
Data were drawn from a randomised clinical trial of desmopressin (an antidiuretic) 
combined with tolterodine (an antimuscarinic agent) in women with overactive 
bladder and nocturia (ClinTrials.gov identifier: NCT01729819). Patients were required 
to have 2 or more nightly voids to be included in the trial, as this has been shown 
to be a clinically-relevant threshold for patient bother. We selected the subgroup 
of patients with NP who completed the Nocturia Impact Diary (a disease-specific 
HRQoL instrument, ranging from 0-100 where low values imply better QoL) and 
the generic EQ-5D-5L (n= 41). The utility analysis was adjusted for age, body mass 
index, baseline number of nightly voids and number of comorbidities. Results: The 
adjusted mean EQ-5D index for 2-3 voids was 0.87 and for 4 or more nightly voids 
0.83 (ns). The adjusted EQ-5D VAS values were similar at 80.5 and 80.6. Unadjusted 
index utility values were 0.88 and 0.81, respectively. The Nocturia Impact Diary total 
scores were 41.5 and 46.8 for the two groups, respectively. ConClusions: The gen-
eral disadvantage of the EQ-5D is that it is relatively insensitive to urinary diseases. 
This analysis suggests, however, that there is a relationship between nocturnal 
polyuria (and nocturia) disease severity, HRQoL and utility.
PUK23
vAlIDAtION Of thE OvERActIvE blADDER QUEStIONNAIRE (OAb-Q; 1-WEEK 
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objeCtives: To confirm the factor structure and evaluate the reliability, validity, 
and responsiveness of the OAB-q in medically complex elderly with overactive 
bladder (OAB). Methods: Post-hoc analyses were conducted using data from a 
12-week clinical trial for urgency urinary incontinence (UUI; N= 566). Structure of 
the OAB-q was evaluated using a confirmatory factor analysis. Cronbach’s coef-
ficient alpha (CCA) was used to assess reliability. Convergent validity was exam-
ined using Pearson’s and Spearmen Product-Moment correlations. Known-groups 
validity was assessed by evaluating differences in OAB-q scores in patients cat-
egorized according to UUI severity (mild, moderate, severe) and Patient Perception 
of Bladder Condition (PPBC) severity (Some Moderate Problems, Severe to Many 
Severe Problems). Effect size was used to examine responsiveness of the OAB-q, 
and an anchor-based approach was used to estimate the clinically important dif-
ference. Results: Participants were mainly female (82.2%) and white (85.9%) with 
a mean age of 75.0 (± 6.4) years. Bentler’s Comparative Fit Index was satisfactory 
(0.90), path coefficients were statistically significant (t-values > 1.96), and all stand-
ardized path coefficients were > 0.40, indicating that a second-order measurement 
model with 5 domains and one aggregated domain holds true in the medically com-
plex elderly population. OAB-q domains demonstrated good internal consistency 
(CCAs > 0.7). Convergent validity was supported by moderate correlations (0.4 – 0.7) 
between OAB-q domains and other related patient-reported outcomes. Significant 
differences in OAB-q domain scores between groups of different severity based on 
UUI and PPBC provided evidence of known-groups validity. Responsiveness was 
demonstrated by statistically significant and clinically relevant differences in mean 
scores for the OAB-q domains over time between Baseline and Week 12 with effect 
sizes of those differences of about 0.2. ConClusions: The OAB-q has reliability, 
sound concurrent and discriminative validity with other measures, responsiveness 
to treatment, and is fit for purpose in medically complex elderly patients with OAB.
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objeCtives: ADPKD imposes substantial burdens on HRQoL at all stages of the dis-
ease. Few studies have examined disease impacts and symptomatology on HRQoL. 
This analysis aimed to assess whether disease-specific questionnaires allow for 
improved assessment of HRQoL in ADPKD. Methods: In a large global observa-
tional study of 3,409 subjects, patient-reported outcomes (PRO) instruments (includ-
ing SF-12v2, EQ-5D, ADPKD-IS) were completed in 6-month intervals. Scores were 
calculated at Baseline and longitudinally, overall and by chronic kidney disease 
(CKD) stage. Results: The overall population scores were normal/near normal 
regardless of instrument with little change overtime (mean score at Baseline and 
18 months): SF-12 Mental Component Summary score (MCS) 50.15 to 49.77, SF-12 
Physical Component Summary score (PCS) 49.94 to 49.12; EQ-5D US Index 0.91 to 
0.90; ADPKD-IS Physical 1.59 to 1.66, Emotional 1.78 to 1.79, Fatigue 1.90 to 1.95. 
Only the SF-12 PCS and ADPKD-IS instruments were able to differentiate between 
early and late stage disease at Baseline (CKD1 vs CKD4 at baseline (SD): PCS 52.22 
(8.41) vs 46.79 (9.89), MCS 49.66 (9.90) vs 51.09 (9.63), EQ-5D US Index 1.06 (0.25) 
vs 1.13 (0.34), ADPKD-IS Physical 1.47 (0.82) vs 1.83 (0.88), Emotional 1.72 (0.88) vs 
2.07 (0.91), Fatigue 1.77 (1.03) vs 2.25 (1.23)). Longitudinal changes (Baseline and 18 
months) could only be measured in later disease stages. Changes in EQ-5D and 
SF-12 were driven by impacts on overall health state. ConClusions: The disease-
specific ADPKD-IS questionnaire was more sensitive to HRQoL in a cross-sectional 
analysis by disease severity vs all generic HRQoL instruments except SF-12 PCS. 
In a slowly progressing disease like ADPKD, observations of longitudinal change 
in HRQoL will require longer follow-up. These results support that ADPKD disease 
impacts are incapable of being measured by blunt generic tools.
